EBMT 2023 - 49th Annual Meeting of the European Group for Bone and Marrow Transplantation
Apr 23 - Apr 26, 2023 | ParisFrance
LARVOL is not affiliated with 49th Annual Meeting of the European Group for Bone and Marrow Transplantation and all trademarks, logos, and brand names are property of their respective owners
Showing 145 abstracts linked to Trials
FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL: 5-YEAR FOLLOW-UP UPDATE
CTX110 ALLOGENEIC CRISPR-CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: RESULTS FROM THE PHASE 1 DOSE ESCALATION CARBON STUDY
LISOCABTAGENE MARALEUCEL FOR RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: FEASIBILITY, SAFETY AND EFFICACY IN A REAL-WORLD SETTING
IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3, A PHASE 3 RANDOMIZED CONTROLLED TRIAL
VEDOLIZUMAB FOR PROPHYLAXIS OF LOWER GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM UNRELATED DONORS: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY
CONTEXT-SPECIFIC ADAPTATION, IMPLEMENTATION AND EVALUATION OF AN EHEALTH-FACILITATED INTEGRATED CARE MODEL WITH CONTINUOUS STAKEHOLDER INVOLVEMENT IN ALLOGENEIC STEM CELL TRANSPLANTATION – THE SWISS SMILE PROJECT
SIMILAR OUTCOMES BUT DIFFERENT EXPERIENCES OF GASTROSTOMY VERSUS NASOGASTRIC TUBE FEEDING IN PEDIATRIC BONE MARROW TRANSPLANT: A MIXED METHODS STUDY
EFFICACY AND SAFETY OF A SINGLE DOSE OF EXAGAMGLOGENE AUTOTEMCEL FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA AND SEVERE SICKLE CELL DISEASE
LOW TOXICITY WITH MYELOABLATIVE CHEMO-BASED CONDITIONING FOR CHILDREN WITH ALL BELOW 4 YEARS OF AGE. RESULTS FROM THE PROSPECTIVE MULTINATIONAL FORUM-TRIAL
UPDATED RESULTS FROM PHASE 3 STUDY TABELECLEUCEL FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE RITUXIMAB(R) OR R+CHEMOTHERAPY (ALLELE)
RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAÏVE OR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE I/II REACH4 STUDY
LENTIVIRAL-MEDIATED EX-VIVO GENE THERAPY FOR PEDIATRIC PATIENTS WITH SEVERE LEUKOCYTE ADHESION DEFICIENCY-I (LAD-I): INTERIM RESULTS FROM AN ONGOING PHASE 1/2 STUDY
BIOCHEMICAL ENGRAFTMENT AND CLINICAL OUTCOMES OF EX-VIVO AUTOLOGOUS STEM CELL GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE IIIA
JIAN JIAN LUAN: ALLOGENEIC TRANSPLANTATION IN ADVANCED CUTANEOUS T-CELL LYMPHOMAS: A PROPENSITY SCORE-MATCHED CONTROLLED PROSPECTIVE TRIAL
EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH STEROID-REFECTORY CHRONIC GRAFT VERSUS HOST DISEASE AFTER CROSSOVER IN THE PHASE 3 REACH-3 STUDY